Researchers describe generation of plasma cell-specific antibody from immunized lampreys

Antibody-secreting plasma cells arise from B cell precursors and are essential for adaptive immune responses against invading pathogens. Plasma cell dysfunction is associated with autoimmune and neoplastic disorders, including multiple myeloma. Surface markers that are specific to plasma cells have not been identified and antibodies that only recognize these cells have been challenging to generate using conventional systems. In the current issue of JCI Insight, Götz Ehrhardt and colleagues at the University of Toronto describe the generation of a plasma cell-specific antibody from immunized lampreys. The authors injected lamprey larvae with a bone marrow isolate from a multiple myeloma patient and screened the resulting monoclonal antibodies for those that recognized both malignant and non-malignant plasma cells. Further characterization of antibody VLRB MM3 revealed that this antibody is specific to plasma cells and does not recognize other B cell populations or progenitors. VLRB MM3 binding was shown to coincide with CD38 dimerization and correlate with and impede the NAD glycohydrolase activity of this glycoprotein. The VLRB MM3 antibody represents a unique tool with potential for both diagnostic and therapeutic applications for plasma cell disorders.

Source: Journal of Clinical Investigation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR